Enliven Therapeutics Inc.
$ 28.32
3.17%
24 Feb - close price
- Market Cap 1,629,084,000 USD
- Current Price $ 28.32
- High / Low $ 28.92 / 27.62
- Stock P/E N/A
- Book Value 8.03
- EPS -1.81
- Next Earning Report 2026-03-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.18 %
- ROE -0.25 %
- 52 Week High 30.22
- 52 Week Low 13.30
About
Enliven Therapeutics Inc. (Ticker: ELVN) is a pioneering biotechnology firm dedicated to revolutionizing the treatment of cancer and other critical diseases through its proprietary therapeutic solutions. The company boasts a robust pipeline of innovative drug candidates that leverage state-of-the-art advancements in biopharmaceutical development, aiming to significantly improve patient outcomes and quality of life. With a strong commitment to scientific rigor and addressing substantial unmet medical needs in oncology, Enliven is well-positioned to deliver value for its shareholders while making a meaningful impact in the healthcare sector.
Analyst Target Price
$41.38
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-13 | 2025-05-12 | 2025-03-12 | 2024-11-07 | 2024-08-13 | 2024-05-14 | 2024-03-14 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-02-10 |
| Reported EPS | -0.32 | -0.49 | -0.57 | -0.46 | -0.4782 | -0.41 | -0.54 | -0.47 | -0.51 | -0.41 | -0.8 | 1.21 |
| Estimated EPS | -0.5 | -0.55 | -0.5043 | -0.5175 | -0.5 | -0.55 | -0.57 | -0.54 | -0.47 | -0.36 | -0.63 | -0.786 |
| Surprise | 0.18 | 0.06 | -0.0657 | 0.0575 | 0.0218 | 0.14 | 0.03 | 0.07 | -0.04 | -0.05 | -0.17 | 1.996 |
| Surprise Percentage | 36% | 10.9091% | -13.028% | 11.1111% | 4.36% | 25.4545% | 5.2632% | 12.963% | -8.5106% | -13.8889% | -26.9841% | 253.944% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-12 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.42 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ELVN
2026-02-21 09:06:16
Enliven Therapeutics (NASDAQ:ELVN) has received an average "Moderate Buy" rating from five brokerages, with four "buy" ratings and one "sell" rating, alongside a one-year average price target of $41.00. Insider activity shows COO Anish Patel and Director Richard A. Heyman selling shares, though insiders still own 25.90% of the company. Institutional investors, including Vestal Point Capital and Vanguard Group, hold 95.08% of the stock and have been increasing their positions.
2026-02-19 01:29:19
Enliven Therapeutics Director Richard Heyman sold 1,230 shares of ELVN stock on February 17th for a total of $32,201.40, reducing his position by 5.15%. The company's stock currently trades around $26.16, with a market cap of $1.55 billion and significant institutional ownership at 95.08%. Analysts maintain a "Moderate Buy" rating with a target price of $41.00.
2026-02-18 00:57:14
Enliven Therapeutics (NASDAQ:ELVN) experienced a 14.1% decrease in short interest in January, with total short interest falling to 7,870,182 shares. This represents 17.9% of shares short and a days-to-cover ratio of 7.9 days based on average daily volume. The article also highlights significant insider selling, institutional holdings, analyst ratings (Moderate Buy with a $41 price target), and the company's financial performance.
2026-02-13 09:50:00
This article from Stock Traders Daily discusses how movement serves as an input in quantitative signal sets for Enliven Therapeutics Inc. (NASDAQ: ELVN). It highlights conflicting sentiment across different time horizons, suggesting choppy conditions and elevated downside risk. The analysis provides AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide potential trades and manage risk.
2026-02-11 09:28:10
Candriam S.C.A. significantly increased its stake in Enliven Therapeutics (NASDAQ:ELVN) by 46.3% in the third quarter, bringing its total holdings to 609,352 shares valued at approximately $12.47 million. Despite recent insider selling, which saw 257,613 shares sold, institutional investors now own 95.08% of the clinical-stage biotech company. Enliven Therapeutics, with a market capitalization of $1.66 billion, recently reported stronger-than-expected earnings and holds an average analyst rating of "Moderate Buy" with a target price of $41.00.
2026-02-11 03:28:06
Enliven Therapeutics (NASDAQ:ELVN) Director Joseph Lyssikatos sold 5,000 shares of the company's stock on February 6th for $145,200.00, reducing his stake by 0.67%. The sale was reported in an SEC filing, and following the transaction, Lyssikatos directly owns 740,188 shares valued at approximately $21.5 million. Analysts currently rate ELVN stock as a "Moderate Buy" with an average price target of $41.00.
